Akrocell Biosciences

Andy Byungho Song brings over 25 years of experience across

global biotech and pharmaceutical business development, spanning

LG Life Sciences, Chong Kun Dang Pharma, and Korean biotech ventures.

His career has centered on translating scientific innovation into real-world

impact — leading global licensing negotiations, partnership development,

and commercialization strategy across human therapeutics.

In November 2024, he pivoted Akrocell's focus toward companion animal

regenerative medicine — recognizing veterinary medicine as a faster, more

direct path to validating species-specific exosome therapeutics at a global

scale. Within a year, the company established its HYCC™ platform, secured

GMP manufacturing capabilities, and built business networks with various

global animal health companies.

M.S., Life Sciences, POSTECH /

MBA, Korea University Business School

Andy Byungho Song brings over 25 years of experience across global biotech and pharmaceutical business development, spanning LG Life Sciences, Chong Kun Dang Pharma, and Korean biotech ventures.

His career has centered on translating scientific innovation into real-world impact — leading global licensing negotiations, partnership development, and commercialization strategy across human therapeutics.

In November 2024, he pivoted Akrocell's focus toward companion animal regenerative medicine — recognizing veterinary medicine as a faster, more direct path to validating species-specific exosome therapeutics at a global scale. Within a year, the company established its HYCC™ platform, secured GMP manufacturing capabilities, and built business networks with various global animal health companies.

M.S., Life Sciences, POSTECH /

MBA, Korea University Business School

Hyo Eun Park is the scientific architect behind the HYCC™ platform.

With over two decades of experience in stem cell and cell therapy research

— spanning academic, translational, and industrial settings — she brings

rare depth in both laboratory science and manufacturing readiness.

Her work at the Seoul St. Mary’s Hospital, Catholic University of Korea and

a Korean biotech venture established her expertise in clinical-grade cell

processing, preclinical program design, and translational execution for human

cell therapeutics— including leading IND clearance for two stem cell

therapeutic pipeline programs.

At Akrocell, she led the development of HYCC™ from concept to GMP-scale

reality — establishing the manufacturing foundation that defines the

company's scientific identity.

M.S., Biomedical Science, Catholic University of Korea

Hyo Eun Park is the scientific architect behind the HYCC™ platform. With over two decades of experience in stem cell and cell therapy research — spanning academic, translational, and industrial settings — she brings rare depth in both laboratory science and manufacturing readiness.

Her work at the Seoul St. Mary’s Hospital, Catholic University of Korea and a Korean biotech venture established her expertise in clinical-grade cell processing, preclinical program design, and translational execution for human cell therapeutics. At Akrocell, she led the development of HYCC™ from concept to GMP-scale reality — establishing the manufacturing foundation that defines the company's scientific identity.

M.S., Biomedical Science, Catholic University of Korea